A decrease in the concentration of MMP-3 in the blood plasma of patients with SSc observed in the present study may be the result of an increase in the activity of tissue matrix metalloproteinase inhibitors, including TIMP-1 and TIMP-2. This evidence concerns the gene TIMP2 and systemic sclerosis.